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Abstract
Apo E plays an important role in plasma lipoprotein metabo-
lism through its high affinity binding to cell surface LDL recep-
tor. In the present study, we studied the effects of apo E on the
atherogenic process in Watanabe heritable hyperlipidemic rab-
bits which are deficient in LDL receptor and an animal model
for familial hypercholesterolemia. We isolated apo E from
plasma of1% cholesterol-fed rabbits and administered 10 mg of
purified apo E intravenously into five Watanabe heritable hy-
perlipidemic rabbits three times a week from their age of 2.5
months to 11 months for 8.5 months. After sustained adminis-
tration ofapo E, we found a significant reduction in the accumu-
lation of cholesterol ester in aortae (1.55±0.07 mg/g tissue) as
compared to control rabbits (4.32±0.61 mg/g tissue). Support-
ing this, the percentage of the surface area of the aorta with
macroscopic plaque was remarkably decreased in apo E-
treated animals (18.8±5.1% vs. 38.8±8.0% in control). Thus,
apo E definitely prevented the progression of atherosclerosis in
Watanabe heritable hyperlipidemic rabbits. (J. Clin. Invest.
1992.89:706-711.) Key words: apolipoprotein E - atherosclero-
sis * Watanabe heritable hyperlipidemic rabbit * low density
lipoprotein receptor * cholesterol
Introduction
Apo E functions in plasma lipoprotein metabolism through its
interaction with cell surface receptors such as LDL receptor
(1-5) and apo E receptor (LDL receptor-related protein) (6, 7).
Recently, we and others demonstrated a reduction in plasma
cholesterol levels after intravenous administration of apo E
into Watanabe heritable hyperlipidemic (WHHL)1 rabbits (8,
9). Exogenous apo E was incorporated into plasma lipoproteins
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including VLDL, then VLDL enriched in apo E was removed
rapidly from the blood through mutant LDL receptor or apo E
receptor in WHHL rabbits, and induced the reduction in
plasma cholesterol levels. This function ofapo E is supposed to
reduce the rate of atherogenesis because many studies have
proved the relationship between plasma cholesterol level and
the incidence of coronary heart disease (10, 1 1).
Many studies have suggested important roles of apo E in
lipid transport in various tissues, including liver, brain, periph-
eral nerves, and arterial walls, as well as in plasma (3, 12-14).
However, in vivo effects of apo E are not fully understood; in
particular, its effects on atherogenesis are controversial. Apo E
secreted from macrophages is proposed to function in choles-
terol efflux from cholesterol-loaded cells collaborating with
HDLs in the interstitial fluid (15, 16); this function is consid-
ered to be related to the regression of atherosclerosis by reduc-
ing intracellular cholesterol of foam cells. In contrast, apo E-
rich lipoproteins such as f3-VLDL and hypertriglyceridemic
VLDL have been considered to be atherogenous from in vitro
studies (17, 18), because macrophages actively endocytose lipo-
proteins containing several molecules of apo E, and transform
to foam cells in vitro. Our recent study also demonstrated the
enhanced uptake of apo E-rich VLDL in human monocyte-
derived macrophages (19). The apo E secreted from macro-
phages can be incorporated into VLDL, and VLDL enriched in
apo E is actively taken up by macrophages with a high affinity
to cell surface receptors. Both functions of apo E that are re-
lated to cholesterol efflux from macrophages and cholesterol
uptake by macrophages, may play an important role in patho-
physiology of atherosclerosis. To understand an overall effect
of apo E on the process of atherosclerosis in vivo, we adminis-
tered rabbit apo E into WHHL rabbits, an animal model of
early atherosclerosis, for 8.5 months in the present study.
Methods
Animal experiments. 10 male WHHL rabbits from six litters, weighing
1.5 kg, were fed laboratory chow ad lib. and housed individually
before and during the experiments.
Apo E. Apo E was purified from plasma of rabbits fed a diet con-
taining 1% cholesterol by weight for > 1 mo. Plasma from blood con-
taining 0.1% EDTA and 0.02% sodium azide was ultracentrifuged at d
= 1.03 g/ml for 20 h at 16'C in a 50.2 rotor of an ultracentrifuge at
45,000 rpm (Beckman Instruments, Inc., Palo Alto, CA); the superna-
tant lipoproteins were recentrifuged under the same condition to ob-
tain lipoproteins rich in apo E (8). All steps ofpurification were carried
out at 4°C. After delipidation ofthe lipoproteins by extraction with 200
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vol of ethanol-ether (1:1) four times and evaporating the solvent under
N2, apolipoproteins were dissolved in 2mM sodium phosphate, pH 7.4
containing 6 M urea, dialyzed against 2 mM sodium phosphate con-
taining 50 mM NaCl and 1 M urea, pH 7.4 (buffer A), and applied to a
column (2 X 16 cm) ofheparin-Sepharose 4B (Pharmacia Fine Chemi-
cals, Uppsala, Sweden) preequilibrated with 2 mM sodium phosphate
containing 50 mM NaCl, pH 7.4 (buffer B). The column was first
washed with 100 ml of buffer A, then with 1,200 ml of buffer B, and
finally with 2 mM sodium phosphate containing 500 mM NaCl and 6
M urea, pH 7.4, to elute apo E. The purity of apo E was evaluated by
SDS polyacrylamide gel electrophoresis (8) and purity was > 99%.
After dialysis against water and lyophilization, purified apo E was
stored at -80'C. One day before use, apo E was dissolved in 6 M
guanidine chloride, pH 7.4, at a concentration of - 20 mg/ml,
and finally dialyzed extensively against 150 mM NaCl. We prepared
- 5 g of apo E for the current study, which was pooled and used as a
single lot.
In vivo studies. The experiment was started at the age of 2.5 mo in
WHHL rabbits. 10 mg of sterile rabbit apo E in 0.5 ml of0.15 M NaCl
was administered intravenously by a bolus injection through a mar-
ginal ear vein every Monday, Wednesday, and Friday morning for 8.5
mo. In control rabbits, 0.5 ml of 0.15 M NaCl was injected to evaluate
the natural course of atherosclerosis. Each animal group consisted of
five rabbits from five litters. Before starting the experiment, and 2 and 6
mo after starting the experiment, 2 ml of blood was taken to measure
plasma cholesterol (20), triglyceride levels by enzymatic methods (21),
and HDL-cholesterol level by precipitation method (22), one day after
apo E injection. After 8.5 mo of the experiment, 5 ml of blood was
drawn to evaluate blood cell counts, liver functions, kidney functions,
and plasma lipid levels.
Extent of atherosclerotic lesions. Animals were killed under deep
anesthesia with xylazine at 7 mg/kg and ketamine at 80 mg/kg intra-
muscularly. The entire aorta from the aortic valve to the iliac bifurca-
tion was removed and cleaned ofloose adventitial tissue. For the analy-
sis, the aorta was divided into three segments at the levels of the first
intercostal artery and celiac artery (aortic arch, descending thoracic
aorta, and abdominal aorta). We measured contents ofcholesteryl ester
in each segment of aorta to confirm macroscopic observations. Each
segment of aorta was dried by lyophilization and stored at -20°C until
analysis. Total lipid extracts were prepared by cutting each aorta into
small pieces and homogenizing three times in chloroform/methanol
(2:1) in a tapered glass-glass homogenizer. Determinations oftotal and
free cholesterol in the extracts were performed in triplicate by enzy-
matic assay.
Furthermore, we determined the extent of lesion area with macro-
scopic atherosclerotic plaques. The aorta was opened longitudinally,
covered with a clear plastic sheet, and copied with a magnification of 2,
then the areas corresponding to atheromatous plaques on the copied
paper were delineated. The delineated areas of atheromatous lesions
were scanned and estimated by computer. The lesion areas within each
segment were summed and the extent of lesions was expressed as per-
centage of surface area with atheromatous plaque.
Statistical analysis. All data were expressed as mean±SD. We com-
pared data between groups by analysis of variance, and the statistical
difference was determined by Student's t tests.
Results
Plasma lipid levels. Plasma cholesterol levels and triglyceride
levels were over 400 mg/dl and 300 mg/dl, respectively, and
plasma HDL-cholesterol levels were 6-9 mg/dl as shown in
Table I. There were no significant differences between the two
groups, but we found decrease in plasma cholesterol levels in
both animal groups after the experiment as compared to before
the experiment. Mean plasma apo E level increased 54% 3 min
Table I. Changes in Plasma Cholesterol, Triglyceride, and HDL-
Cholesterol Levels (mg/dl) after the Administration ofRabbit
apo E (n = 5) and Saline (n = 5) in Male WHHL Rabbits
Months after starting experiments
Group 0 2 6 8.5
Cholesterol (mg/dl)
Apo E 502±33 490±39 431±83 408±42
Control 518±15 512±19 440±65 418±46
Triglyceride (mg/dl)
Apo E 415±91 422±116 325±67 328±59
Control 365±82 368±122 387±93 378±181
HDL-cholesterol
(mg/dl)
Apo E 7.0±2.2 6.0±1.7 6.0±0.86 6.0±1.5
Control 8.2±1.6 6.8±2.0 6.7±1.9 7.9±1.0
Serum lipid levels were measured by enzymatic assay. Male WHHL
rabbits weighing - 1.5 kg were fed laboratory chow ad lib. Apo E
was purified from plasma of rabbits fed a diet containing 1% choles-
terol by weight for more than 1 month (6). We prepared ~-5 g of apo
E for the current study, which was pooled and used as a single lot.
The experiment was started at the age of 2.5 months in WHHL
rabbits. We checked the daily intake of diet every day; there were no
significant differences in the mean food consumption. Body weight
gains during the experiment were not significantly different between
the two groups. We did not find any differences in peripheral blood
cell counts, liver functions or kidney functions between the groups
after 8.5 months of treatment.
Values are expressed as mean ± SD.
after apo E injection as compared to preinjection level, and the
half-life of injected apo E was 1.5 h in a different set of studies
using WHHL rabbits (n = 3). We checked daily intake of diet
every day; there were no significant differences in the mean
food consumption. Body weight gains during the experiment
were not significantly different between the two groups
(1.5±0.1 to 3.2±0.2 kg: apo E 1.5±0.1 to 3.2±0.2 kg: saline).
We did not find any differences in peripheral blood cell counts,
liver functions, and kidney functions between the two groups
after 8.5 months treatment.
Extent of aortic atherosclerosis. There was a remarkable
reduction in the accumulation of cholesterol ester in aortae
from animals treated with apo E as compared with those
treated with saline (apo E: 1.55 mg/g aorta, saline: 4.32 mg/g
aorta, Table II). The accumulation of cholesterol ester in each
segment of aorta was significantly less in animals treated with
apo E than those with saline (P < 0.001, Table II). Supporting
these observations, the lesion area with atherosclerotic plaque
in the apo E group was much smaller than that in the saline
group (18.8% vs. 38.8%, P < 0.002, Table III and Fig. 1). In
particular, the extent of the lesion area in the aortic arch was
very different between these two groups (P < 0.001). Percent-
ages oflesion areas ofdescendingthoracic aorta and abdominal
aorta in animals treated with apo E were significantly different
from those with saline (P < 0.02 and P < 0.02, respectively).
Visual examinations showed the thickness of atherosclerotic
plaques to be apparently minimal in animals treated with apo
E (Fig. 1). In the immunocytochemical study with antibody
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Table II. Contents ofCholesterol Ester ofEach Aortic Arch, Descending Thoracic Aorta, Abdominal Aorta, and Total Aorta
in WHHL Rabbits Treated with Rabbit apo E or Saline
Cholesterol ester (mg)
Group Aortic arch Thoracic Abdominal Total aorta Cholesterol ester/dry tissue
Apo E-1 0.20 0.10 0.08 0.38 1.58
Apo E-2 0.21 0.11 0.03 0.35 1.52
Apo E-3 0.21 0.11 0.10 0.42 1.50
Apo E-4 0.19 0.08 0.02 0.31 1.48
Apo E-5 0.20 0.18 0.05 0.43 1.65
Mean±SD 0.20±0.01* 0.12±0.04* 0.06±0.03* 0.38±0.05* 1.55±0.07*
Control-i 0.56 0.21 0.12 0.89 3.87
Control-2 0.71 0.25 0.18 1.14 4.75
Control-3 0.68 0.34 0.17 1.19 4.76
Control-4 0.61 0.35 0.15 1.11 3.47
Control-5 0.68 0.35 0.16 1.19 4.76
Mean±SD 0.65±0.06 0.30±0.07 0.16±0.02 1.10±0.12 4.32±0.61
* P < 0.001. Cholesterol ester/dry tissue indicates contents of cholesterol ester (in milligrams) per weight of dry total aorta (in grams). The apo E
group was compared to the saline group. Each segment of aorta was dried by lyophilization and stored at -20'C until analysis. Total lipid
extracts were prepared by cutting each aorta into small pieces and homogenizing it three times in chloroform/methanol (2: 1) in a tapered glass-
glass homogenizer. Determinations of total and free cholesterol in the extracts were performed in triplicate by enzymatic assay.
specific for smooth muscle cells (HHF 35) and macrophages
(RAM 11) (23), we found the similar distribution of both cell
types in the atherosclerotic lesions of both groups. As com-
pared to the percentage lesion area, the cholesterol ester con-
Table III. Percentages ofIntimal Surface Area with Atheromatous
Plaque ofEach Aortic Arch, Descending Thoracic Aorta,
Abdominal Aorta, and Total Aorta in WHHL Rabbits
Treated with Rabbit apo E or Saline
Percent lesion area
Group Aortic arch Thoracic Abdominal Total aorta
Apo E-1 30 9 9 14
ApoE-2 33 11 5 14
ApoE-3 41 15 9 18
Apo E-4 34 30 13 25
Apo E-5 42 24 8 23
Mean±SD 36.0±5.2* 17.8±8.9* 8.8±2.9$ 18.8±5.1I
Control-l 54 32 10 27
Control-2 86 30 18 38
Control-3 78 51 26 49
Control-4 77 30 16 38
Control-5 82 40 23 42
Mean±SD 75.4±12.5 36.6±9.0 18.6±6.2 38.8±8.0
* P < 0.001; $ P < 0.02; § p < 0.002. The apo E group was compared
to the control group. The entire aorta from the aortic valve to the
iliac bifurcation was removed and opened longitudinally. The aorta,
covered with a clear plastic sheet, was copied with a magnification
of 2 and the area corresponding to atheromatous plaques on the cop-
ied paper was delineated. The delineated areas of atheromatous
lesions were estimated as lesioned area. The aorta was divided into
three segments at the levels of the first intercostal artery and celiac
artery (aortic arch, descending thoracic aorta, and abdominal aorta).
tents of the aortae were extremely reduced in animals treated
with apo E, and those variations among animals were much
smaller. When the ratios of cholesterol ester accumulation to
lesion area were compared between two groups, we could not
find significant differences in the ratios between the two groups
as shown in Fig. 2.
Discussion
In recent studies, we have suggested the possible involvement
of apo E in the process of atherosclerosis (8, 19). The present
study tried to determine the effects of apo E on its process in
vivo. One of the best ways to evaluate the effects of agents that
can affect the rate ofatherogenesis in vivo is long-term adminis-
tration of such agents to young WHHL rabbits that have not
yet developed atherosclerotic lesions (24, 25). Plasma choles-
terol levels in WHHL rabbits are > 400 mg/dl, and severe,
progressive atherosclerosis occurs after the age of 4 months
(26). In the present study, we injected a relatively low dose of
apo E (10 mg/animal per day) into young WHHL rabbits (2.5
months) as compared to the previous study, in which apo E was
shown to significantly reduce plasma cholesterol levels after
treatment with 30-40 mg of apo E. Minimal effects on plasma
cholesterol level have been demonstrated in WHHL rabbits
after intravenous injection of 10 mg of apo E (27). During the
experimental period, there were no significant differences in
plasma lipid levels between the two groups.
Apo E definitely reduced the rate of atherogenesis after 8.5
months of treatment in WHHL rabbits. The cholesterol accu-
mulation and lesion area were reduced approximately one-
third and one-half, respectively, in animals treated with apo E
as compared to those with saline. The cholesterol ester content
ofeach aortic segment was well correlated to percentage lesion
area (r = 0.884). Similar retarded progression ofatherosclerosis
without significant change in plasma cholesterol level was dem-
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Figure 1. Aortic specimens obtained
from WHHL rabbits. The upper two
aortae are from rabbits (saline-2 and
saline-3) in the saline group. The
lower two aortae are from rabbits
(apo E-l and apo E-2) in the apo E
group. 10 mg of sterile rabbit apo
E in 0.5 ml of 0.15 M NaCl was ad-
ministered intravenously by a bolus
injection through a marginal ear
vein every Monday, Wednesday,
and Friday morning for 8.5 mo.
Animals were killed under deep an-
esthesia with xylazine at 7 mg/kg
and ketamine at 80 mg/kg intra-
muscularly. The entire aorta from
the aortic valve to the iliac bifurca-
tion was removed and cleaned of
loose adventitial tissue. In the saline
group, 0.5 ml of0.15 M NaCl was
injected as control.
onstrated only in WHHL rabbits given probucol (25). Micro-
scopic examination has shown that there was no significant
change in subintimal cellular proliferation between the two
groups.
Many factors have been suspected of being involved in the
generation of foam cells in the arterial wall: accumulation of
cholesterol in and efflux of cholesterol from macrophages, re-
cruitment of circulating monocytes, and functions ofendothe-
lial cells and smooth muscle cells. Ifthere were an imbalance in
these factors such as the high plasma cholesterol level and low
HDL cholesterol level found in WHHL rabbits, the rate of
atherogenesis would be accelerated. The results of our study
suggest that apo E is very effective in correcting the imbalance
of factors which determine the rate of atherogenesis. Because
there were no significant differences in plasma cholesterol lev-
els between the two groups during the experimental period (Ta-
ble I), the effects of apo E on the process of atherosclerosis
might not be related to plasma cholesterol level, although there
were minimal and acute effects of low dose apo E on plasma
cholesterol levels.
Apo E secreted from macrophages in peripheral tissues is
suggested to be involved in cholesterol transport from periph-
eral tissues to liver, which is called a reverse cholesterol trans-
port system (3, 15, 16). Cholesterol-loaded cells such as macro-
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Figure 2. Ratios of cholesterol ester accumulation (mg/g aorta) to
percentage lesion area in apo E and saline groups.
phages release their cholesterol to either HDL or other acceptor
proteins including apo E and apo Al in the interstitial fluid. In
vitro studies showed that the presence of apo E facilitates the
acquisition ofcholesterol byHDL (15), and apo E itselfactively
accepts cholesterol from cholesterol-loaded cells (28). HDL
with apo E or apo E-lipid complex, after accepting cellular
cholesterol, can bind to hepatic receptors including LDL recep-
tors and apo E receptors by virtue of the presence of apo E on
lipoproteins. Thus, the extracholesterol accumulating in the
subendothelial foam cells can be transported with apo E to the
liver, where it is removed by receptor-mediated endocytosis.
Because HDL concentrations are low in WHHL rabbits (6-9
mg/dl) as compared to normal rabbits (20-25 mg/dl) (29), exog-
enous apo E either associated with or without HDL (HDL with
apo E or free form ofapo E) may help the function ofHDL in
the reverse cholesterol transport system, and may accelerate
the turnover of this system.
In addition to the effects of apo E on lipoprotein metabo-
lism, apo E influences the functions of lymphocytes and
smooth muscle cells, which are major cell components of arte-
rial walls. Apo E inhibits mitogenic stimulation oflymphocytes
by binding to specific sites on the surface oflymphocytes (30),
and apo E produced by smooth muscle cells may be involved in
modulating cell proliferation and differentiation (3). It is possi-
ble that cellular functions influenced by the presence of apo E
play important roles in reducing the rate of atherogenesis in
WHHL rabbits. In addition, macrophage function is important
in foam cell formation because an early atherosclerotic lesion is
characterized by the presence of macrophage-derived foam
cells. Recently, it has been demonstrated that LDL receptor-re-
lated protein, a candidate for apo E receptor, is identical to a2
macroglobulin receptor that appears on macrophages (31). The
function of macrophages can be altered by the presence ofapo
E through its binding to a2 macroglobulin receptor. The al-
tered function of macrophages may influence the mechanism
of foam cell generation in the arterial wall.
In vitro studies demonstrated that lipoproteins rich in apo
E can be actively taken up by macrophages and generate foam
cells (17, 18). When we studied the uptake ofVLDL enriched
in apo E which had been incubated with excess apo E in human
monocyte-derived macrophages and hep G2 cells, enrichment
of apo E doubled the lipoprotein uptake to a similar extent in
both cell types, indicating no preferential uptake of lipopro-
teins enriched in apo E in macrophages (32). Current results
demonstrating no acceleration of the rate of atherogenesis in
WHHL rabbits, also suggest that sustained apo E injection does
not specifically enhance foam cell formation through the mech-
anism of the uptake of apo E-rich lipoproteins by macro-
phages. In the present study, we have investigated an overall
effect ofapo E in vivo. Although the precise mechanism ofapo
E action in the prevention of atherosclerosis is yet unknown,
exogenous apo E may influence the rate ofatherogenesis by not
only activating the reverse cholesterol transport system but also
modifying cellular functions in the arterial wall, rather than by
enhancing the cholesterol accumulation in the arterial wall.
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